Substance / Medication

Clemastine fumarate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Drug repurposing: Clemastine fumarate and neurodegeneration.
Zhu Jiahui, Ma Rong, Li Gang · Biomed Pharmacother · 2023
PMID: 36370521Review
Simple accessible clemastine fumarate analogues as effective antileishmanials.
Charlton Rebecca L, Escrivani Douglas O, Brown Christopher et al. · RSC Med Chem · 2025
PMID: 40017824OtherFull text (PMC)
Measurement and modeling of clemastine fumarate (antihistamine drug) solubility in supercritical carbon dioxide.
Sodeifian Gholamhossein, Garlapati Chandrasekhar, Razmimanesh Fariba et al. · Sci Rep · 2021
PMID: 34934101OtherFull text (PMC)
Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis.
Kocot Joanna, Kosa Peter, Ashida Shinji et al. · J Clin Invest · 2025
PMID: 40371642TrialFull text (PMC)
Clemastine fumarate alleviates endoplasmic reticulum stress through the Nur77/GFPT2/CHOP pathway after ischemia/reperfusion in rat hearts.
He Yuling, Sun Fan, Song Caixuan et al. · Int Immunopharmacol · 2025
PMID: 39929094Preclinical
Promotion of the genipin crosslinked chitosan-fiber hydrogel loaded with sustained release of clemastine fumarate in diabetic wound repair.
Zuo Rongtai, Shi Jingjing, Jiang Susu et al. · Int J Biol Macromol · 2023
PMID: 36502950Preclinical
Clemastine fumarate attenuates tauopathy and meliorates cognition in hTau mice via autophagy enhancement.
Zhu Jiahui, Jiang Xingjun, Chang Yanmin et al. · Int Immunopharmacol · 2023
PMID: 37494840Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Clemastine fumarate (substance)
SNOMED CT
83968007
UMLS CUI
C0546858

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.